Ocugen, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Ocugen, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | $0 | Feb 28, 2022 |
| FY2021 | Dec 31, 2020 | $43.0K | Feb 28, 2022 |
| FY2021 | Dec 31, 2019 | $0 | Feb 28, 2022 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.41M | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | $4.06M | Mar 4, 2026 |
| FY2024 | Dec 31, 2023 | $6.04M | Mar 5, 2025 |
| FY2023 | Sep 30, 2023 | $3.70M | Apr 16, 2024 |
| FY2023 | Jun 30, 2023 | $485.0K | Apr 16, 2024 |
| FY2023 | Mar 31, 2023 | $443.0K | Apr 16, 2024 |
| FY2023 | Dec 31, 2022 | $2.49M | Apr 16, 2024 |
| FY2023 | Sep 30, 2022 | $466.0K | Apr 16, 2024 |
| FY2023 | Jun 30, 2022 | $643.0K | Apr 16, 2024 |
| FY2023 | Mar 31, 2022 | $500.0K | Apr 16, 2024 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $0 | Mar 15, 2018 |
| FY2017 | Dec 31, 2016 | $0 | Mar 15, 2018 |
| FY2016 | Dec 31, 2015 | $0 | Mar 16, 2017 |
| FY2015 | Dec 31, 2014 | $0 | Mar 10, 2016 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($67.85M) | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | ($54.05M) | Mar 4, 2026 |
| FY2024 | Jun 30, 2024 | ($15.28M) | Mar 5, 2025 |
| FY2024 | Mar 31, 2024 | ($11.92M) | Mar 5, 2025 |
| FY2024 | Dec 31, 2023 | ($63.08M) | Mar 5, 2025 |
| FY2023 | Sep 30, 2023 | ($11.72M) | Apr 16, 2024 |
| FY2023 | Jun 30, 2023 | ($23.07M) | Apr 16, 2024 |
| FY2023 | Mar 31, 2023 | ($17.33M) | Apr 16, 2024 |
| FY2023 | Dec 31, 2022 | ($86.80M) | Apr 16, 2024 |
| FY2023 | Sep 30, 2022 | ($23.91M) | Apr 16, 2024 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($62.92M) | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | ($54.76M) | Mar 4, 2026 |
| FY2024 | Dec 31, 2023 | ($65.53M) | Mar 5, 2025 |
| FY2023 | Sep 30, 2023 | ($12.43M) | Apr 16, 2024 |
| FY2023 | Jun 30, 2023 | ($23.54M) | Apr 16, 2024 |
| FY2023 | Mar 31, 2023 | ($18.04M) | Apr 16, 2024 |
| FY2023 | Dec 31, 2022 | ($89.07M) | Apr 16, 2024 |
| FY2023 | Sep 30, 2022 | ($25.11M) | Apr 16, 2024 |
| FY2023 | Jun 30, 2022 | ($21.58M) | Apr 16, 2024 |
| FY2023 | Mar 31, 2022 | ($19.03M) | Apr 16, 2024 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $39.75M | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | $32.13M | Mar 4, 2026 |
| FY2024 | Dec 31, 2023 | $39.57M | Mar 5, 2025 |
| FY2019 | Dec 31, 2019 | $8.09M | Mar 27, 2020 |
| FY2019 | Dec 31, 2018 | $10.32M | Mar 27, 2020 |
| FY2018 | Dec 31, 2017 | $15.57M | Mar 22, 2019 |
| FY2017 | Dec 31, 2016 | $21.58M | Mar 15, 2018 |
| FY2016 | Dec 31, 2015 | $23.24M | Mar 16, 2017 |
| FY2015 | Dec 31, 2014 | $26.04M | Mar 10, 2016 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($56.96M) | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | ($42.14M) | Mar 4, 2026 |
| FY2024 | Dec 31, 2023 | ($62.05M) | Mar 5, 2025 |
| FY2023 | Sep 30, 2023 | ($50.75M) | Apr 16, 2024 |
| FY2023 | Jun 30, 2023 | ($37.05M) | Apr 16, 2024 |
| FY2023 | Mar 31, 2023 | ($18.24M) | Apr 16, 2024 |
| FY2023 | Dec 31, 2022 | ($60.08M) | Apr 16, 2024 |
| FY2023 | Sep 30, 2022 | ($43.17M) | Apr 16, 2024 |
| FY2023 | Jun 30, 2022 | ($28.86M) | Apr 16, 2024 |
| FY2023 | Mar 31, 2022 | ($15.07M) | Apr 16, 2024 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $185.0K | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | $3.39M | Mar 4, 2026 |
| FY2024 | Dec 31, 2023 | $10.48M | Mar 5, 2025 |
| FY2023 | Sep 30, 2023 | $7.75M | Apr 16, 2024 |
| FY2023 | Jun 30, 2023 | $4.39M | Apr 16, 2024 |
| FY2023 | Mar 31, 2023 | $1.61M | Apr 16, 2024 |
| FY2023 | Dec 31, 2022 | $4.46M | Apr 16, 2024 |
| FY2023 | Sep 30, 2022 | $2.43M | Apr 16, 2024 |
| FY2023 | Jun 30, 2022 | $1.59M | Apr 16, 2024 |
| FY2023 | Mar 31, 2022 | $223.0K | Apr 16, 2024 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $43.52M | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | $82.44M | Mar 4, 2026 |
| FY2024 | Dec 31, 2023 | $64.55M | Mar 5, 2025 |
| FY2023 | Sep 30, 2023 | $74.69M | Apr 16, 2024 |
| FY2023 | Jun 30, 2023 | $88.98M | Apr 16, 2024 |
| FY2023 | Mar 31, 2023 | $96.30M | Apr 16, 2024 |
| FY2023 | Dec 31, 2022 | $108.63M | Apr 16, 2024 |
| FY2023 | Sep 30, 2022 | $116.24M | Apr 16, 2024 |
| FY2023 | Jun 30, 2022 | $130.09M | Apr 16, 2024 |
| FY2023 | Mar 31, 2022 | $141.73M | Apr 16, 2024 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $55.68M | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | $52.81M | Mar 4, 2026 |
| FY2024 | Dec 31, 2023 | $23.98M | Mar 5, 2025 |
| FY2023 | Sep 30, 2023 | $24.89M | Apr 16, 2024 |
| FY2023 | Jun 30, 2023 | $29.73M | Apr 16, 2024 |
| FY2023 | Mar 31, 2023 | $31.40M | Apr 16, 2024 |
| FY2023 | Dec 31, 2022 | $34.65M | Apr 16, 2024 |
| FY2023 | Sep 30, 2022 | $30.55M | Apr 16, 2024 |
| FY2023 | Jun 30, 2022 | $23.61M | Apr 16, 2024 |
| FY2023 | Mar 31, 2022 | $16.21M | Apr 16, 2024 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($12.17M) | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | $29.63M | Mar 4, 2026 |
| FY2025 | Dec 31, 2023 | $40.56M | Mar 4, 2026 |
| FY2023 | Sep 30, 2023 | $49.80M | Apr 16, 2024 |
| FY2023 | Jun 30, 2023 | $59.24M | Apr 16, 2024 |
| FY2023 | Mar 31, 2023 | $64.90M | Apr 16, 2024 |
| FY2024 | Dec 31, 2022 | $73.98M | Mar 5, 2025 |
| FY2023 | Sep 30, 2022 | $85.69M | Apr 16, 2024 |
| FY2023 | Jun 30, 2022 | $106.48M | Apr 16, 2024 |
| FY2023 | Mar 31, 2022 | $125.52M | Apr 16, 2024 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($408.07M) | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | ($340.22M) | Mar 4, 2026 |
| FY2024 | Dec 31, 2023 | ($286.17M) | Mar 5, 2025 |
| FY2023 | Sep 30, 2023 | ($275.20M) | Apr 16, 2024 |
| FY2023 | Jun 30, 2023 | ($263.48M) | Apr 16, 2024 |
| FY2023 | Mar 31, 2023 | ($240.42M) | Apr 16, 2024 |
| FY2023 | Dec 31, 2022 | ($223.09M) | Apr 16, 2024 |
| FY2023 | Sep 30, 2022 | ($200.70M) | Apr 16, 2024 |
| FY2023 | Jun 30, 2022 | ($176.78M) | Apr 16, 2024 |
| FY2023 | Mar 31, 2022 | ($155.30M) | Apr 16, 2024 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $39.46M | Apr 16, 2024 |
| FY2023 | Sep 30, 2023 | $53.48M | Apr 16, 2024 |
| FY2023 | Jun 30, 2023 | $70.58M | Apr 16, 2024 |
| FY2023 | Mar 31, 2023 | $68.26M | Apr 16, 2024 |
| FY2023 | Dec 31, 2022 | $77.56M | Apr 16, 2024 |
| FY2023 | Sep 30, 2022 | $101.60M | Apr 16, 2024 |
| FY2023 | Jun 30, 2022 | $115.01M | Apr 16, 2024 |
| FY2023 | Mar 31, 2022 | $129.77M | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | $94.96M | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | $24.04M | Feb 28, 2022 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | $1.71M | Feb 28, 2022 |
| FY2021 | Dec 31, 2020 | $2.06M | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | $1.07M | Mar 19, 2021 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | 0 | Apr 16, 2024 |
| FY2023 | Sep 30, 2023 | 0 | Apr 16, 2024 |
| FY2023 | Jun 30, 2023 | 0 | Apr 16, 2024 |
| FY2023 | Mar 31, 2023 | 0 | Apr 16, 2024 |
| FY2023 | Dec 31, 2022 | 0 | Apr 16, 2024 |
| FY2023 | Sep 30, 2022 | 0 | Apr 16, 2024 |
| FY2023 | Jun 30, 2022 | 0 | Apr 16, 2024 |
| FY2023 | Mar 31, 2022 | 0 | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Feb 28, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | 0 | Apr 16, 2024 |
| FY2023 | Sep 30, 2023 | 0 | Apr 16, 2024 |
| FY2023 | Jun 30, 2023 | 0 | Apr 16, 2024 |
| FY2023 | Mar 31, 2023 | 0 | Apr 16, 2024 |
| FY2023 | Dec 31, 2022 | 0 | Apr 16, 2024 |
| FY2023 | Sep 30, 2022 | 0 | Apr 16, 2024 |
| FY2023 | Jun 30, 2022 | 0 | Apr 16, 2024 |
| FY2023 | Mar 31, 2022 | 0 | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Feb 28, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 312.38M | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | 291.37M | Mar 4, 2026 |
| FY2024 | Dec 31, 2023 | 256.57M | Mar 5, 2025 |
| FY2023 | Dec 31, 2022 | 221.60M | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | 199.38M | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | 184.01M | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | 52.63M | Mar 19, 2021 |
| FY2019 | Dec 31, 2018 | 4.96M | Mar 27, 2020 |
| FY2018 | Dec 31, 2017 | 24.57M | Mar 22, 2019 |
| FY2017 | Dec 31, 2016 | 20.65M | Mar 15, 2018 |